About: COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ‐ Is there any scientific evidence for controversy?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ‐ Is there any scientific evidence for controversy? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ‐ Is there any scientific evidence for controversy?
Creator	Ippolito, G Zumla, A Aleksova, A Beltrami, A Cappelletto, C Ferro, F Gagno, G Rossi, M Santon, D Sinagra, G
source	Medline; PMC
abstract	Renin–angiotensin system (RAS) blockers are extensively used worldwide to treat many cardiovascular disorders, where they are effective in reducing both mortality and morbidity. These drugs are known to induce an increased expression of angiotensin‐converting enzyme 2 (ACE2). ACE2 acts as receptor for the novel SARS coronavirus‐2 (SARS‐CoV‐2) which raising the important issue of possible detrimental effects that RAS blockers could exert on the natural history and pathogenesis of the coronavirus disease‐19 (COVID‐19) and associated excessive inflammation, myocarditis and cardiac arrhythmias. We review the current knowledge on the interaction between SARS‐CoV‐2 infection and RAS blockers and suggest a scientific rationale for continuing RAS blockers therapy in patients with COVID‐19 infection.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.1111/joim.13101
bibo:pmid	32459372
has license	no-cc
sha1sum (hex)	41f412dfd752b60ff571c7de5da330a0f4715168
schema:url	https://doi.org/10.1111/joim.13101
resource representing a document's title	COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ‐ Is there any scientific evidence for controversy?
has PubMed Central identifier	PMC7283873
has PubMed identifier	32459372
schema:publication	J Intern Med
resource representing a document's body	covid:41f412dfd752b60ff571c7de5da330a0f4715168#body_text
is schema:about of	named entity 'converting' named entity 'upregulation' named entity 'ARBs' named entity 'ACE2' named entity 'viral replication' named entity 'SARS-CoV' named entity 'heart failure' named entity 'pro-inflammatory' named entity 'SARS-CoV' named entity '17 March 2020' named entity 'ARBs' named entity 'myocardial tissue' named entity 'heart failure' named entity 'ACE2' named entity 'cytokine' named entity 'G-CSF' named entity 'protein expression' named entity 'blood pressure' named entity 'ACEIs' named entity 'disseminated intravascular coagulation' named entity 'cardiac involvement' named entity 'pathogenesis' named entity 'receptor' named entity 'older age' named entity 'fibroblasts' named entity 'cigarette smoking' named entity 'RNA viruses' named entity 'human coronavirus' named entity 'virus entry' named entity 'ARBs' named entity 'SARS-CoV' named entity 'myocardial infarction' named entity 'IL-10' named entity 'ACE2' named entity 'autopsy' named entity 'ACE2' named entity 'RAS' named entity 'ACE2' named entity 'COVID-19' named entity 'infection' named entity 'nucleocapsid' named entity 'SARS-CoV-2' named entity 'diabetic' named entity 'correlation' named entity 'COVID' named entity 'atherosclerotic plaques' named entity 'inflammatory cytokines' named entity 'ACE2' named entity 'pathogens' named entity 'angiotensin-converting enzyme 2' named entity 'ACE2' named entity 'vascular permeability' named entity 'plasma' named entity 'metabolites' named entity 'ARBs' named entity 'Ang1' named entity 'ACE2' named entity 'ARBs' named entity 'case report' named entity 'smooth muscle cell' named entity 'macrophage' named entity 'COVID-19' named entity 'antiviral drugs' named entity 'ALI' named entity 'virus' named entity 'COVID' named entity 'CD68' named entity 'receptor' named entity 'ACE2' named entity 'vascular permeability' named entity 'ACE2' named entity 'RAS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software